

**Purified Influenza A Virus,
A/Brisbane/59/2007 (H1N1)
(Tissue Culture Adapted)**

Catalog No. NR-48598

For research use only. Not for human use.

Contributor and Manufacturer:

BEI Resources

Product Description:

Virus Classification: *Orthomyxoviridae, Influenzavirus A*

Species: Influenza A virus

Strain/Isolate: A/Brisbane/59/2007 (tissue culture adapted)

Source: NR-48598 was purified from BEI Resources NR-31657 (influenza A virus, A/Brisbane/59/2007 (H1N1) (tissue culture adapted)). NR-31657 was derived through tissue culture adaptation of BEI Resources NR-12282 which was isolated in 2007 from a 47-year-old female in Brisbane, Australia. After isolation, this strain was passaged in eggs at the CDC, followed by two egg passages at Baylor College of Medicine prior to deposit. NR-31657 was passaged nine times in Madin-Darby canine kidney (MDCK) cells at BEI Resources.

Comments: Sequence information is available for influenza A virus, A/Brisbane/59/2007 (H1N1) at the [Influenza Research Database](#). The World Health Organization recommended influenza A/Brisbane/59/2007 (H1N1)-like viruses for use as vaccines during the 2008-2009 and 2009-2010 Northern Hemisphere influenza seasons and during the 2009 Southern Hemisphere influenza season.^{1,2}

NR-48598 was prepared by inoculation of MDCK cells (ATCC[®] CCL-34[™]) with influenza A virus, A/Brisbane/59/2007 (H1N1) (tissue culture adapted) (BEI Resources NR-31657). The virus was purified from clarified supernatant by high speed centrifugation.

Material Provided:

Each vial contains approximately 1 mL of NR-48598 in Dulbecco's phosphate buffered saline (DPBS).

Packaging/Storage:

NR-48598 was packaged aseptically in screw-capped plastic cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.

Growth Conditions:

Host: MDCK cells (ATCC[®] CCL-34[™])

Growth Medium: Minimum Essential Medium supplemented with 2 µg per mL L-1-tosylamido-2-phenylethyl chloromethyl ketone (TPCK)-treated trypsin and 0.125%

Bovine Serum Albumin, or equivalent.

Infection: Cells should be 90% to 100% confluent

Incubation: 2 to 6 days at 35°C and 5% CO₂

Cytopathic Effect: Cell rounding and detachment

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Purified Influenza A Virus, A/Brisbane/59/2007 (H1N1) (Tissue Culture Adapted), NR-48598."

Biosafety Level: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmb15/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC[®] nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC[®] nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC[®] and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC[®], their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. <http://www.who.int/influenza/vaccines/vaccinerecommendations1/en/index1.html>
2. Fiore, A. E., et al. "Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010." *MMWR Recomm. Rep.* 59 (2010): 1-62. PubMed: 20689501.

ATCC® is a trademark of the American Type Culture Collection.

